Skin Cancer/Precancer

SKIN CANCER/PRECANCER

FEATURE ARTICLE

African American black patient dermoscope melanoma

Skin Cancer and Multi-Ethnic Dermatology: Q&A with Dr Margareth Pierre-Louis

Margareth Pierre-Louis, MD, MBA, FAAD discusses issues pertaining to skin cancer in people with skin of color as well as recommendations for the provision of multi-ethnic dermatology care.

LATEST NEWS

A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities.

Stopping Ipi/Nivo for irAEs Did Not Affect Advanced Melanoma Survival

Leah Lawrence

Immune-related adverse events were associated with improved survival outcomes.

Two cases raise the question of whether abnormal activation of the hedgehog signaling pathway can le

Genetic and Epigenetic Characteristics and Latest Therapies for Melanomas

Estie Mermelstein, MSN, FNP-BC

The main genetic and epigenetic findings of melanomas and their pathologic and therapeutic significance is reviewed.

Keytruda Approved for Locally Advanced Cutaneous Squamous Cell Carcinoma

Brian Park, PharmD

Results showed an overall response rate of 50%, with 17% of patients achieving complete response and 33% having partial response.

Poll: Many ‘High-Risk’ Americans Unconcerned About Skin Cancer

A new poll shows that only about 30% of American adults say they are concerned about developing skin cancer — even though nearly 70% have at least one risk factor for the disease.

The FDA has approved ipilimumab (Yervoy) for adjuvant treatment of stage 3 cutaneous melanoma after

Study Supports Routine PET-CT Surveillance for Asymptomatic, High-Risk Melanoma

Christina Bennett, MS

PET-CT results led to management changes in 15% of patients.

Improved strategies may be needed for cancer prevention, screening, and surveillance among solid org

Barriers to Physician Skin Exam Identified for Young Melanoma Survivors

Barriers to health care access, especially cost, are associated with increased odds of not having an annual physician skin examination (PSE) among young melanoma survivors.